HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yaghoubi, S. Articles by Gambhir, S. S. Search for Related Content PubMed PubMed Citation Articles by Yaghoubi, S. Articles by Gambhir, S. S.

Human Pharmacokinetic and Dosimetry Studies of [¹⁸F]FHBG: A Reporter Probe for Imaging Herpes Simplex Virus Type-1 Thymidine Kinase Reporter Gene Expression

Crump Institute for Molecular Imaging, UCLA–DOE Laboratory of Structural Biology and Molecular Medicine; Department of Molecular and Medical Pharmacology, Division of Nuclear Medicine; Molecular Biology Institute; Department of Biomathematics; and Jonsson Comprehensive Cancer Center, UCLA School of Medicine, University of California, Los Angeles, California

View larger version (68K): [in a new window]   FIGURE 1. Whole-body coronal images of [18F]FHBG biodistribution in healthy volunteer (subject 8) at 4 times after 167.6-MBq (4.53-mCi) intravenous injection of PET tracer. Images are sum of 30 coronal planes (12–15 mm thick per plane). [18F]FHBG clears from other organs into intestines and bladder over time.

View larger version (16K): [in a new window]   FIGURE 2. Time–activity curves of [18F]FHBG in bladder (A), intestines (B), liver (C), and kidneys (D) of healthy volunteer (subject 8). Activities were decay corrected to time of injection; graphs indicate biologic clearance of [18F]FHBG into bladder and intestines and out of liver and kidneys. Graphs indicate percentage of total injected activity in each organ versus time after injection of [18F]FHBG tracer.

View larger version (13K): [in a new window]   FIGURE 3. Time–activity curve of [18F]FHBG in whole blood (WB) and plasma of healthy volunteer (subject 8). [18F]FHBG is removed from blood rapidly, and most activity is in plasma portion. Average ratio of activity in plasma to activity in whole blood during approximately 2 h after tracer injection was 0.888 for this person.

View larger version (11K): [in a new window]   FIGURE 4. Percentage of stable [18F]FHBG found in urine samples of healthy volunteers 2.5 h after injection of [18F]FHBG tracer. [18F]FHBG elutes from anion exchange column at 6 min. This analysis shows that 82.94% ± 9.31% (n = 10) of total activity found in urine specimens was stable [18F]FHBG.